Stable S/MAR-based episomal vectors are regulated at the chromatin level
- First Online:
- Cite this article as:
- Tessadori, F., Zeng, K., Manders, E. et al. Chromosome Res (2010) 18: 757. doi:10.1007/s10577-010-9165-4
Episomal vectors assembled from defined genetic components are a promising alternative to traditional gene therapy vectors that integrate in the host genome and may cause insertional mutations. The vector pEPI-eGFP is stably retained in the episomal state in cultured mammalian cells at low copy number for many generations without integration into the host genome. Although pEPI-eGFP is a fully engineered vector, little is known about how it interacts with the host genome and about the molecular mechanisms that are responsible for its transcriptional activity. We have analyzed the expression of the episomal reporter gene eGFP under conditions that affect the chromatin state of the genome. We have also constructed pEPI derivatives carrying a tandem array of lac operator sequences, which allows in vivo visualization and manipulation of the chromatin state of the episome. We show that changes in chromatin state of both the host and pEPI-eGFP induces changes in episomal gene activity and influences the episome’s nuclear distributions. We conclude that episomal genes are subject to control systems of the host, similarly to their counterparts in the host genome.
Chinese hamster ovary K1
Enhanced green fluorescence protein
Fetal bovine serum
Fluorescence in situ hybridization
Human colorectal tumor 16
Herpes simplex virus
Immortalized mouse embryonic fibroblast
Lac operator / Lac repressor
Nuclear localization signal
Scaffold/matrix attachment region
Suppressor of variegation 3-9 h1
The stable and safe transfer of genes to mammalian and in particular human cells is of great interest for biomedical and biotechnological research. A number of transformation techniques have been developed (reviewed in Conese et al. 2004; Glover et al. 2005; Jackson et al. 2006; Van Craenenbroeck et al. 2000), most of which employ vectors that assure stable expression by integration in the host genome. However, integration can disrupt host genes and position effects make expression of the transgene unpredictable (Hacein-Bey-Abina et al. 2003a; Hacein-Bey-Abina et al. 2003b). As an alternative, non-integrating episomal vectors have been developed. Such episomes are often based on viral sequences (Conese et al. 2004; Van Craenenbroeck et al. 2000). They can be retained in the episomal state in the host cell during cell division, may have a stable level of gene expression and are assumed not to be subject to position effects because of their non-integrated state. However, since viral gene products can be detrimental due to immunological complications or undesired interactions with host cell components, their use in humans is restricted (reviewed in Glover et al. 2005; Lipps et al. 2003).
Recently, a fully engineered non-viral episomal vector (pEPI-eGFP) has been developed that may be a safe alternative for gene transfer in mammals (Stehle et al. 2007; Jenke et al. 2004b; Baiker et al. 2000; Piechaczek et al. 1999). After transfection pEPI-eGFP becomes a persistent episome in mammalian cells. This property is attributed to the combination of a 2 kb S/MAR (scaffold/matrix attachment region) sequence, which has been isolated from the human β-interferon locus, and read-through transcription of a gene into the S/MAR sequence (Jackson et al. 2006; Jenke et al. 2004b; Stehle et al. 2003). Episomal pEPI-eGFP is claimed to be present in cells at low copy numbers, typically 2–10 per cell, based on fluorescence in situ hybridization (FISH) labeling (Baiker et al. 2000; Jenke et al. 2004b; Stehle et al. 2007). Interestingly, pEPI-eGFP not only remains episomal in cultured cells, it was also found to persist in various tissues of pig fetuses after sperm-mediated transfer into the embryo, illustrating the robustness of the S/MAR-based episomal system (Manzini et al. 2006). These properties make pEPI-eGFP a promising vector for applications that aim at permanent genetic transformation of mammals, including gene therapy in man.
Despite the potential of the pEPI-GFP-type episomes, we have only limited understanding of the molecular mechanisms that ensure their extra-chromosomal persistence and regulate expression of their genes. Issues such as episomal replication, faithful segregation during mitosis, and control of transcription have hardly been addressed yet. It has been shown that persistent pEPI-eGFP replicates once per cell cycle in early S-phase (Schaarschmidt et al. 2004) and acquires a nucleosomal organization enriched in marks for transcriptionally active chromatin, such as trimethylated histone H3K4 (Stehle et al. 2007). Interestingly, these marks are particularly enriched at the S/MAR sequence in pEPI-eGFP in a cell-cycle-dependent manner (Rupprecht and Lipps 2009). Thus, although pEPI-eGFP is a stable extra-chromosomal replicon, its chromatin state is at least in part controlled by the host. For genes integrated in the host genome it is well documented that the local nuclear environment plays an important role in gene expression, often by affecting the chromatin state (Finlan et al. 2008, reviewed in Fraser and Bickmore 2007; Kumaran et al. 2008; Zhao et al. 2009). Whether such processes also act in trans, affecting episomes, is unknown.
To get insight into in trans-regulatory mechanisms between host and episomal chromatin we have combined in vivo 3D live cell microscopy with molecular analysis of the episome by chromatin immunoprecipitation (ChIP). Using the lac operator/lac repressor (lacO/lacR) system (Robinett et al. 1996; Verschure et al. 2005), we have visualized individual episomes in living cells and manipulated their functional state. Results show that transcriptional activation is accompanied by a moderate relocation of the episomes towards nuclear center. We provide evidence that episomes can be transcriptionally activated by changing the chromatin state of the host and likely also of the episome, in particular by inhibiting DNA methylation, decreasing histone H3K9 tri-methylation and inhibiting histone deacetylation. We show that an increase in acetylated episomal histone H3 is correlated with enhanced episomal transcription. Taken together, our data suggest that episomal genes behave remarkably similar to host genes.
Materials and methods
Cultured cells and transfection
Chinese Hamster Ovary (CHO-K1) cells were grown in Ham’s F12 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen), 100 units/ml penicillin and 100 units/ml streptomycin (Invitrogen). Suv39h1-/- cells and immortalized mouse embryonic fibroblasts (IMEFs) were grown as described elsewhere (Peters et al. 2001). HCT116 cells were cultured in McCoy’s 5A medium (Invitrogen) supplemented with 10% heat-inactivated FBS (Invitrogen), 100 units/ml penicillin and 100 units/ml streptomycin (Invitrogen). All cells were cultured at 37°C with 5% CO2. Transfection of all cells was carried out with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. For the establishment of cell lines that persistently carry the episomal vector, 24 h after transfection with the episomal construct, CHO-K1, Suv39h1−/− and IMEF cells were selected on culture medium supplemented with respectively 500 μg/ml G418 (CHO-K1 cells) or 400 μg/ml G418 (Suv39h1−/− and IMEF cells) for 3 weeks. The selected cells were subsequently cultured with a 2-fold lower concentration of G418 (Invitrogen). Transient transfection with mCherry-lac repressor for in vivo observations was carried out following the same protocol and cells were analyzed 48 to 72 h after transfection.
DNA isolation and Southern blot analysis
Total genomic DNA was isolated from 106 CHO-K1 cells and digested with the appropriate restriction enzyme; 5 μg DNA of each sample were subsequently separated on 0.8% agarose gel and blotted overnight to a nylon membrane (Fluka, Buchs SG, Switzerland). A polymerase chain reaction (PCR)-amplified 609-bp fragment, synthesized with the primers 5′-GACGTAAACGGCCACAAGTT-3′ and 5′-GAACTCCAGCAGGACCATGT-3′ on the eGFP sequence, was labeled with 32P and used as a probe.
Fluorescence in situ hybridization
FISH analysis was carried out essentially as described elsewhere (Goetze et al. 2007). Prior to the RNAse treatment a 5-min incubation in 0.1 mg/ml pepsin in 0.01 M HCl was added. pELO64 DNA was used as a probe and labeled with either Biotin- or Digoxigenin-Nick Translation kits (Roche, Mannheim, Germany). Prior to microscopy samples were counterstained with 4′, 6′-diamidino-2-phenylindole (DAPI; 1 μg/ml in Vectashield, Vector Laboratories, Burlingame, CA, USA).
Confocal scanning laser microscopy for in vivo and FISH observation
Images were taken with a Zeiss LSM 510 (Zeiss, Oberkochen, Germany) confocal laser scanning microscope using a 63X Plan-A (1.4 NA) oil immersion objective (Zeiss). For imaging eGFP, Alexa-488 and fluorescein an argon 488-nm laser was used for excitation. Emitted fluorescence was detected using a 505–530-nm band pass filter. For imaging mCherry a 568-nm krypton laser was used for excitation. Emitted fluorescence was detected with a 585-nm-long pass filter. For imaging DAPI-stained DNA, a 364-nm UV laser was used. Emitted fluorescence was detected with a 385–470-nm band pass filter.
In vivo microscopic observations
In vivo observations were carried out on a Zeiss 200 M (Zeiss) inverted fluorescence microscope with a 20X Plan-N (0.75 NA) air objective (Zeiss). For imaging green fluorescence (eGFP) a 490-nm short-pass excitation filter was used. The emitted fluorescence was detected by a 525–565-nm band pass filter. Images were recorded with a cooled CCD camera (Coolsnap HQ, Roper Scientific, Tucson, AZ, USA).
Image analysis on confocal three-dimensional z-stacks was carried out using Argos software (http://homepages.cwi.nl/~wimc/argos). The Mann–Whitney U test for two non-parametric, independent groups was carried out using GraphPad Prism software (GraphPad Software, San Diego, CA, USA). The integrated density of individual mCherry-tagged episomal spots was measured on confocal 3D image stacks. For each spot the intensity was measured in all relevant optical sections (usually just one section), using ImageJ freeware (http://rsb.info.nih.gov/ij/). Regions of interest (ROIs) were defined containing the spot and values were corrected for the intensity in ROIs of the same size in the same section, not containing an episomal spot.
Cells were trypsinized and resuspended in PBS-B (1 × BS; 0.5% (w/v) BSA). For fluorescence analysis, eGFP and mCherry fluorescence were excited by lasers with 488- and 543-nm wavelengths, respectively. FACS distributions were analyzed by segmentation of the distribution of mCherry fluorescence intensity versus eGFP fluorescence intensity. For quantification of eGFP fluorescence, 2D distributions were segmented as shown in Figs. 4b and 7b. Points in the lower right section represented cells with above background eGFP expression.
Trichostatin A and 5-aza-2′-deoxycytidine treatments
CHO-K1, IMEFs, and Suv39h1−/− cells were grown in medium supplemented with trichostatin A (TSA; 25, 50, and 100 ng/ml; Sigma, Zwijndrecht, The Netherlands), 5-aza-2′-deoxycytidine (5, 25, and 50 μM; Fluka), or both drugs simultaneously. eGFP fluorescence was evaluated microscopically or by FACS analysis after 48, 72, and 96 h growth in the presence of the drugs. For the two-tailed Student’s t test (MS Excel, Microsoft, Redmond, WA, USA) was used to identify statistical significance differences (Fig. 6).
Chromatin immunoprecipitation was performed as described previously (Hatzis et al. 2008). In brief, CHO-K1/pEPI-eGFP cells were cross-linked with 1% formaldehyde for 20 min. at room temperature. The reaction was quenched with glycine at a final concentration of 125 mM. The cells were subsequently washed with phosphate-buffered saline, buffer B (0.25% Triton-X 100, 10 mM ethylenediaminetetraacetic acid (EDTA), 0.5 mM ethylene glycol tetraacetic acid (EGTA), 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; pH 7.6)), and buffer C (0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, and 20 mM HEPES (pH 7.6)) at 4°C for 10 min each. The cells were then resuspended in ChIP incubation buffer (0.3% sodium dodecyl sulfate (SDS), 1% Triton-X 100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, and 20 mM HEPES (pH 7.6)) and sheared using a Covaris S2 (Covaris, Woburn, MA, USA) sonicator for 10 min with following settings: duty cycle, max; intensity, max; cycles/burst, max. The final average size of chromatin fragments was 500–1,000 bp. Sonicated chromatin was incubated for 12 h at 4°C with a rabbit-raised polyclonal anti-H3 antibody (ab 1791; Abcam plc, Cambridge, UK)—this antibody recognizes both the non-acetylated state as the acetylated form of histone H3—or a rabbit-raised polyclonal anti-pan-acetyl-H3 (06-599, Upstate-Millipore, Billerica, MA, USA) at a concentration of 2 μg of antibody per 106 cells with protein G beads (Upstate, Lake Placid, NY, USA). The beads were successively washed two times with buffer 1 (0.1% SDS, 0.1% deoxycholate, 1% Triton-X 100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, and 20 mM HEPES (pH 7.6)), one time with buffer 2 (0.1% SDS, 0.1% sodium deoxycholate, 1% Triton-X 100, 0.5 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES (pH 7.6)), one time with buffer 3 (0.25 M LiCl, 0.5% sodium deoxycholate, 0.5% NP-40, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES (pH 7.6)), and two times with buffer 4 (1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES (pH 7.6)) for 5 min each at 4°C. Precipitated chromatin was eluted by incubation of the beads with elution buffer (1% SDS, 0.1 M NaHCO3) at room temperature for 20 min. After washing and elution, immune-precipitated chromatin was de-cross-linked by incubation at 65°C for 5 h in the presence of 200 mM NaCl, extracted with phenol-chloroform, and ethanol precipitated.
Quantitative PCR (qPCR) in an iCycler iQ Real-Time PCR Detection System (BIORAD, Hercules, CA, USA), using iQ SYBR Green Supermix (BIORAD), was carried out for analysis of ChiP experiments. The manufacturer’s recommendations were followed. The reaction volume of each qPCR reaction was 25 μl with a final concentration of 0.8 μM for each primer. All primers used in this work have been published previously in Stehle et al. (2007) and Rupprecht and Lipps (2009) with the exception of primers for the Neo/Kan sequence on pEPI-eGFP (5′-GATCTGGACGAAGAGCATCAG-3′ and 5′- GCCAACGCTATGTCCTGATAG-3′) and the primers on intron 2 of the C. griseus Rhodopsin gene (GenBank accession number: X61084.1; 5′-TAGGGACAGTGGTTTGGT-3′ and 5′-GGTGCGGCTTTTAGAAACA-3′) used as endogenous control. ChIP values are expressed as % of input. The results were collected over a minimum of three technical replicates.
To allow in vivo visualization and manipulation of pEPI-eGFP we constructed the modified episome pELO64 (Fig. 1a), based on pEPI-eGFP (Baiker et al. 2000; Piechaczek et al. 1999). pEPI-eGFP contains the following functional elements: (1) a human S/MAR sequence (isolated from the human INF-beta gene), which is essential for episomal persistence, (2) a selection marker conveying G418 resistance to transfected cells, and (3) the reporter gene eGFP that reads through into the S/MAR sequence. pELO64 (Fig. 1b) in addition carries a tandem array of 64 copies of the lac operator (lacO) sequence (2.5 kb) to visualize the episome in vivo and to target chromatin modifiers, using the lacO–lacR technology (Belmont 2001). Cell lines that persistently carry pELO64 or pEPI-eGFP were made as described previously (Baiker et al. 2000; Jenke et al. 2004b; Rupprecht and Lipps 2009; Stehle et al. 2007). Three weeks after transfection with the episome and culturing in selection medium (500 μg/ml G418 for CHO-K1 cells), Southern analysis showed that pELO64 is present as a single band (Fig. 1d; 9.2 kb), which is the expected result for the episomal state (Piechaczek et al. 1999; Stehle et al. 2003). Integration in the host genome would result in multiple bands of different sizes, as shown by others (Piechaczek et al. 1999; Stehle et al. 2003; Jenke et al. 2004b). Removing the selection pressure does not affect the persistence of the episome in the host cells (Piechaczek et al. 1999; data not shown). However, to ensure the presence of pELO64 in all cells, the concentration of the selecting agent G418 was kept at 250 μg/ml throughout all experiments. Transient expression of the mCherry-lac repressor fusion protein (mCherry-lacR; Fig. 1c; Shaner et al. 2004) allows visualization of the pELO64 episome in vivo and in fixed cells. The mCherry-lacR gene is under control of a weak polyoma promoter to avoid high background fluorescence of unbound protein.
Visualization of the pELO64 episome in the interphase nucleus
Our results on in vivo mCherry labeling and FISH analysis in fixed cells show that the CHO-K1 cells contain on average about two pELO64 episomes per nucleus.
Expression of the episomal eGFP reporter gene
Chromatin-modifying drugs affect episomal expression levels
We have manipulated the chromatin state of the episome and analyzed its effect on gene eGFP expression. This was done in four different ways: (1) increasing histone acetylation by inhibiting histone deacetylase (HDAC) activity by culturing in the presence of the HDAC inhibitor TSA, (2) decreasing the DNA methylation level by inhibiting DNA methyl transferase (DMT) activity by culturing cells in the presence of 5-aza-2′-deoxycytidine, (3) decreasing histone H3 lysine 9 tri-methylation (H3K9Me3) by establishing episomes in IMEFs deficient for the heterochromatic histone methyltransferase (HMT) Su(Var)3–9, using the parent wild-type strain as a control (Peters et al. 2001), and (4) targeting the acidic activation domain of the viral transcriptional activator VP16 to the lacO array on the episome (Chuang et al. 2006; Tumbar and Belmont 2001). The first three approaches affect episomal and host chromatin alike, the fourth specifically targets the episome.
CHO-K1/pELO64 cells were treated with the DMT inhibitor 5-aza-2′-deoxycytidine (5-aza-dC; 48 h, 5 and 50 μM); (Jones 1985), with the HDAC inhibitor TSA (48 h, 25 and 100 ng/ml); (Yoshida et al. 1990), and with a combination of the two drugs. In these experiments, we measured two aspects of eGFP expression by FACS analysis: (1) the fraction of cells that express eGFP (open bars), and (2) the average expression per cell (filled bars, Fig. 4a). The percentage of CHO-K1 cells that contain detectable levels of eGFP is 5% in non-treated cultures (Fig. 4a; control). Treatment with TSA or 5-aza-dC (25 and 100 ng/ml TSA; 5 and 50 μM 5-aza-dC, 48 h) resulted in an up to 3.6- and a 3-fold increase in the percentage of cells with detectable eGFP expression, respectively (Fig. 4a; 100 ng/ml TSA; 50 μM 5-aza-dC, open bars). Simultaneous treatment with TSA and 5-aza-dC did not reveal synergy between the two drugs (not shown). Figure 4b shows the FACS diagrams on which the histogram is based. Clearly, there is a gradual increase in expression, rather than an on-off type of switching of the eGFP gene. In all cases there is no detectable expression in a considerable fraction of cells. These results indicate that the activity of genes on the episome is directly or indirectly affected by a reduction of histone deacetylase activity and of DNA methylation. In this sense the episomal gene behaves the same as host genes.
Increased eGFP expression is accompanied by an increased histone acetylation level on the episome
Episomal expression levels are controlled by various chromatin-mediated mechanisms
To analyze the role of inhibition of episomal gene expression by histone H3K9 methylation, the pEPI-eGFP episome was established in mutant mouse embryonic fibroblasts that do not express the enzyme HMT Suv39h1 (Peters et al. 2001). Our choice was motivated by the fact that, although Suv39h1 is prominently known for its role in methylating H3K9 in constitutive heterochromatin (Lehnertz et al. 2003), it has been shown that in IMEFs the activity of other HMTs depend on the presence of Suv39h1 (Fritsch et al. 2010). This includes the HMTs G9a and GLP, which are thought to be responsible for methylation of H3K9 in euchromatin (Tachibana et al. 2005). Choosing Suv39h1−/− cells, which display a broad spectrum of H3K9 methylation defects (Fritsch et al. 2010), was thus the most likely to affect the episomal chromatin state. Indeed, these cells show an about 2-fold higher basal eGFP expression (Fig. 6b) than their parental wild-type cell line (Fig. 6a), suggesting that H3K9 methylation plays a role in repressing episomal gene expression in IMEFs. Increasing histone acetylation by inhibiting HDAC activity with TSA results in eGFP expression in close to 100% of the Suv39h1−/− cells after 96 h (Fig. 6b; TSA (25 ng/ml) and TSA (50 ng/ml), dark gray bars), as was also observed for wild-type cells (Fig. 6a, TSA (25 ng/ml) and TSA (50 ng/ml), dark gray bars). Interestingly, the transcriptional stimulation by inhibition of DNA methyltransferase in the Suv39h1−/− cells (Fig. 6b; 5-aza-dC (5 μM) and 5-aza-dC (25 μM)) is considerably stronger than in wild-type cells (Fig. 6a; 5-aza-dC (5 μM) and 5-aza-dC (25 μM)), irrespective of the treatment duration (48-, 72-, or 96-h treatments) resulting in eGFP expression in up to about 90% of the cells after 96 h (Fig. 6b; 5-aza-dC (25 μM), dark gray bar). This underscores that, in addition to histone H3K9 methylation and histone de-acetylation, DNA methylation also contributes to silencing of the episome and indicates that the episomal state of pEPI-eGFP and its derivatives does not exempt them from control by various cellular silencing processes.
Targeting of VP16 results in enhanced episomal gene expression
Spatial distribution and mobility of the episome inside the nucleus
Artificial S/MAR-containing episomal vectors, such as the pEPI-eGFP, have properties that make them promising for stable and safe gene transfer, including gene therapy, without integration into the host genome (Baiker et al. 2000; Jackson et al. 2006; Jenke et al. 2004b; Lufino et al. 2007; Manzini et al. 2006; Stehle et al. 2007). These episomes avoid the risk of insertional mutagenesis and the uncertainty of transgene expression due to position effects. Here we focus on the regulation of expression of episomal genes and chromatin state, using the pEPI-eGFP derived pELO64 vector (carrying a 64 tandem array of LacO sites) in two different mammalian cell lines as a model system. Our main conclusion is that the regulatory mechanisms that act on episomal genes seem to be similar to those that control host genes. In particular, trans-acting mechanisms that affect chromatin by changing histone modifications and DNA methylation levels play a role in episomal gene regulation.
In cultures of CHO-K1 cells and IMEFs only a fraction of the cells (5% to 24%, respectively) express detectable levels of the episomal eGFP reporter gene (Figs. 2, 3, 4, 5, and 6). Similar and higher values (22% up to 60%) have been reported for other mammalian host cell lines with pEPI episomes that do not contain LacO repeats (Nehlsen et al. 2006; Papapetrou et al. 2006), underscoring that pEPI expression levels are cell-type dependent. This indicates that the LacO array of the pELO episome has little or no effect on the expression of the reporter gene. Results discussed below suggest that cell-type-dependent effects may in part depend on the balance between different types of chromatin-affecting signals in the cell. It has been suggested that the CMV promoter sequence, which drives eGFP expression in pEPI-eGFP, is prone to epigenetic silencing in rodent cells (Brooks et al. 2004). However, when we established pEPI-eGFP persistence in the human colorectal carcinoma cell line HCT116, only 7% to 12% of the cells expressed eGFP to detectable levels (data not shown), indicating that the low reporter gene expression observed in CHO-K1 and IMEF cells is not rodent-specific.
The low number of eGFP-expressing cells is remarkable, since under G418 selection pressure each cell must contain one or more episomes that express the neomycin resistance gene. It may be argued that non-expressing cells lose the episome or the eGFP marker gene for instance by recombination or during mitosis. However, pEPI episomes have been shown to be persistent in mammalian cells for many cell cycles and during development (Stehle et al. 2007; Jenke et al. 2004b; Schaarschmidt et al. 2004; Baiker et al. 2000; Manzini et al. 2006). Moreover, we grow the cells in the presence of G418, which requires permanent presence of the drug resistance gene. Finally, the observation that after treatment with for instance TSA the fraction of expressing cells increases from about 20% to 99% shows that the marker gene is not lost, which is consistent with the histone deacetylation-induced silencing mechanism of pEPI-eGFP genes proposed by (Papapetrou et al. 2006). Altogether, this makes it very likely that the cells that do not express eGFP do carry the episome in a silenced state.
Expression of the pEPI-eGFP reporter gene is dependent on the chromatin state of the episome. It has been shown that pEPI chromatin undergoes the same modifications as host chromatin (Rupprecht and Lipps 2009; Stehle et al. 2007). Our results show that inhibition of HDAC activity affects the episomal chromatin by increasing the level of histone H3 acetylation similar to the host genome, i.e. it increases histone acetylation and activates gene expression (Figs. 4 and 5). FACS analyses show that the global induction of histone acetylation does not just switch on the eGFP reporter gene. Rather, it increases the average expression level, resulting in a wide range of expression levels (Fig. 4b). Interestingly, different elements of the episome are acetylated to a different extent after TSA treatment. Particularly the pCMV promoter and the polyA site become highly acetylated, probably directly related to increased transcriptional activation of the episome. In contrast to TSA and 5-aza-dC treatment, targeting of the lacO-mCherry-VP16 acidic domain chimeric protein to the lacO array is an episome-specific way of gene activation (Fig. 7). The acidic domain of VP16 is known to recruit histone acetyl-transferase activity (Tumbar et al. 1999). FACS analysis shows that, like the effect of TSA, VP16 targeting increases the average expression level of the eGFP gene, rather than just switching on the gene. The observed activation of eGFP expression by VP16 is another example showing that episomal genes behave similarly to host genes.
Global changes in histone H3K9 methylation also affect pEPI eGFP expression. Episomes in IMEF cells that are deficient in H3K9 methyl transferase are transcriptionally more active compared with the wild-type cell line, implying that H3K9 methylation has an inhibitory effect on episomal transcription (Fig. 6). Similarly, experiments using the DNA methyltransferase inhibitor 5-aza-dC show that DNA methylation suppresses episomal gene expression (Figs. 4 and 6). These effects may be direct by changing episomal chromatin or indirect via changing host properties. Although likely, it is not certain that pEPI episomes undergo DNA methylation and H3K9 methylation as literature on the subject is either contradictory (Argyros et al. 2008; Papapetrou et al. 2006; Jenke et al. 2004a) or lacks detail (Stehle et al. 2007). Interestingly, if mutant mouse cells that lack H3K9 methyltransferase were exposed to 5-aza-dC, their eGFP expression levels increased significantly more than after a similar treatment of wild-type IMEFs (Fig. 6), indicating synergy between the H3K9 methylation and DNA methylation systems (Fuks 2005).
We present microscopic evidence that cells stably contain between 1 and 3 spots that contain one or more episome molecules per interphase nucleus (Fig. 2). Earlier studies found similar numbers based on FISH labeling (Baiker et al. 2000; Nehlsen et al. 2006; Stehle et al. 2007). Our results confirm those studies using FISH on fixed cells and in vivo mCherry labeling, using the lacO/lacR method (Fig. 2; Belmont 2001). Remarkably, episomes are not motile at a time scale of tens of minutes and do not show a corralled type of local low amplitude movement, suggesting that they are firmly bound to host chromatin or other nuclear structures (Fig. 9 and Electronic supplementary material (Movie 1)). Evidence has been presented that episomes preferentially interact with early replication sites (Stehle et al. 2007), which are distributed throughout the nucleoplasm. This may be related to the finding that pEPI episomes are often attached to metaphase chromosomes in metaphase spreads (Baiker et al. 2000; Jenke et al. 2004b; Nehlsen et al. 2006; Stehle et al. 2007). Alternatively, immobilization could be due to binding to nucleoskeletal structures via the S/MAR sequence (Jenke et al. 2002). Despite this immobility, episome seem to reallocate to positions closer to the nuclear center if their gene expression is up-regulated by the targeting of mCherry-lacR-VP16 acidic domain (Fig. 8). This is similar to what is observed for genomic loci, i.e., transcriptionally highly active chromosomes and sub-chromosomal domains are located closer to the nuclear center than genomic areas that are less active (Cremer and Cremer 2001; Goetze et al. 2007; Lanctot et al. 2007).
In summary, our results seem to indicate that regulatory mechanisms affect episomal genes in a similar manner as host genes. This indicates that for application in gene therapy-specific epigenetic control elements must be incorporated in pEPI-like episomal vectors to assure reliable gene expression in a wide range of cell types and physiological conditions.
The authors wish to thank Wim de Leeuw (University of Amsterdam, The Netherlands) for his help with image analysis and use of the Argos software, Pantelis Hatzis and Jurian Schuijers (Hubrecht Institute, Utrecht, The Netherlands) for help and advice with the ChIP and qPCR protocols, Berend Hooibrink (FACS facility, AMC, Amsterdam, The Netherlands) for the FACS analysis, Roger Tsien (UC San Diego, CA, USA) for the kind gift of the mCherry gene, Thomas Jenuwein (Research Institute of Molecular Pathology, Vienna, Austria) for the Suv39h1−/− mouse embryonic fibroblasts and Hanil Quirindongo and Diewertje Piebes (University of Amsterdam) for their assistance in designing and making the lacR fusion proteins. This work was supported by the European Commission as part of the EPI-Vector program, contract LSH-2003-1.2.4-7.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.